A phase 1B/2 study of the CD123-targeting antibody-drug conjugate pivekimab sunirine (IMGN632) in combination with venetoclax (VEN) and azacitidine (AZA) for patients with CD123-positive AML
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Conference item |
| Language: | English |
| Published: |
Wolters Kluwer Health, Inc.
2022
|
| _version_ | 1824459003409727488 |
|---|---|
| author | Daver, NG Montesinos, P Aribi, A Martinelli, G Altman, J Roboz, G Wang, ES Burke, PW Jeyakumar, D Walter, RB DeAngelo, DJ Erba, HP Advani, A Gastaud, L Thomas, X Todisco, E Pemmaraju, N Mendez, L de la Fuente, A Gaidano, G Curti, A Boissel, N Recher, C Schliemann, C Vyas, P Sloss, CM Wang, J Malcolm, KA Zweidler‐McKay, PA Sweet, KL |
| author_facet | Daver, NG Montesinos, P Aribi, A Martinelli, G Altman, J Roboz, G Wang, ES Burke, PW Jeyakumar, D Walter, RB DeAngelo, DJ Erba, HP Advani, A Gastaud, L Thomas, X Todisco, E Pemmaraju, N Mendez, L de la Fuente, A Gaidano, G Curti, A Boissel, N Recher, C Schliemann, C Vyas, P Sloss, CM Wang, J Malcolm, KA Zweidler‐McKay, PA Sweet, KL |
| author_sort | Daver, NG |
| collection | OXFORD |
| description | |
| first_indexed | 2025-02-19T04:34:52Z |
| format | Conference item |
| id | oxford-uuid:7b0132d1-6bad-4736-8f00-38170a35ec34 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2025-02-19T04:34:52Z |
| publishDate | 2022 |
| publisher | Wolters Kluwer Health, Inc. |
| record_format | dspace |
| spelling | oxford-uuid:7b0132d1-6bad-4736-8f00-38170a35ec342025-01-28T13:10:38ZA phase 1B/2 study of the CD123-targeting antibody-drug conjugate pivekimab sunirine (IMGN632) in combination with venetoclax (VEN) and azacitidine (AZA) for patients with CD123-positive AMLConference itemhttp://purl.org/coar/resource_type/c_c94fuuid:7b0132d1-6bad-4736-8f00-38170a35ec34EnglishSymplectic ElementsWolters Kluwer Health, Inc.2022Daver, NGMontesinos, PAribi, AMartinelli, GAltman, JRoboz, GWang, ESBurke, PWJeyakumar, DWalter, RBDeAngelo, DJErba, HPAdvani, AGastaud, LThomas, XTodisco, EPemmaraju, NMendez, Lde la Fuente, AGaidano, GCurti, ABoissel, NRecher, CSchliemann, CVyas, PSloss, CMWang, JMalcolm, KAZweidler‐McKay, PASweet, KL |
| spellingShingle | Daver, NG Montesinos, P Aribi, A Martinelli, G Altman, J Roboz, G Wang, ES Burke, PW Jeyakumar, D Walter, RB DeAngelo, DJ Erba, HP Advani, A Gastaud, L Thomas, X Todisco, E Pemmaraju, N Mendez, L de la Fuente, A Gaidano, G Curti, A Boissel, N Recher, C Schliemann, C Vyas, P Sloss, CM Wang, J Malcolm, KA Zweidler‐McKay, PA Sweet, KL A phase 1B/2 study of the CD123-targeting antibody-drug conjugate pivekimab sunirine (IMGN632) in combination with venetoclax (VEN) and azacitidine (AZA) for patients with CD123-positive AML |
| title | A phase 1B/2 study of the CD123-targeting antibody-drug conjugate pivekimab sunirine (IMGN632) in combination with venetoclax (VEN) and azacitidine (AZA) for patients with CD123-positive AML |
| title_full | A phase 1B/2 study of the CD123-targeting antibody-drug conjugate pivekimab sunirine (IMGN632) in combination with venetoclax (VEN) and azacitidine (AZA) for patients with CD123-positive AML |
| title_fullStr | A phase 1B/2 study of the CD123-targeting antibody-drug conjugate pivekimab sunirine (IMGN632) in combination with venetoclax (VEN) and azacitidine (AZA) for patients with CD123-positive AML |
| title_full_unstemmed | A phase 1B/2 study of the CD123-targeting antibody-drug conjugate pivekimab sunirine (IMGN632) in combination with venetoclax (VEN) and azacitidine (AZA) for patients with CD123-positive AML |
| title_short | A phase 1B/2 study of the CD123-targeting antibody-drug conjugate pivekimab sunirine (IMGN632) in combination with venetoclax (VEN) and azacitidine (AZA) for patients with CD123-positive AML |
| title_sort | phase 1b 2 study of the cd123 targeting antibody drug conjugate pivekimab sunirine imgn632 in combination with venetoclax ven and azacitidine aza for patients with cd123 positive aml |
| work_keys_str_mv | AT daverng aphase1b2studyofthecd123targetingantibodydrugconjugatepivekimabsunirineimgn632incombinationwithvenetoclaxvenandazacitidineazaforpatientswithcd123positiveaml AT montesinosp aphase1b2studyofthecd123targetingantibodydrugconjugatepivekimabsunirineimgn632incombinationwithvenetoclaxvenandazacitidineazaforpatientswithcd123positiveaml AT aribia aphase1b2studyofthecd123targetingantibodydrugconjugatepivekimabsunirineimgn632incombinationwithvenetoclaxvenandazacitidineazaforpatientswithcd123positiveaml AT martinellig aphase1b2studyofthecd123targetingantibodydrugconjugatepivekimabsunirineimgn632incombinationwithvenetoclaxvenandazacitidineazaforpatientswithcd123positiveaml AT altmanj aphase1b2studyofthecd123targetingantibodydrugconjugatepivekimabsunirineimgn632incombinationwithvenetoclaxvenandazacitidineazaforpatientswithcd123positiveaml AT robozg aphase1b2studyofthecd123targetingantibodydrugconjugatepivekimabsunirineimgn632incombinationwithvenetoclaxvenandazacitidineazaforpatientswithcd123positiveaml AT wanges aphase1b2studyofthecd123targetingantibodydrugconjugatepivekimabsunirineimgn632incombinationwithvenetoclaxvenandazacitidineazaforpatientswithcd123positiveaml AT burkepw aphase1b2studyofthecd123targetingantibodydrugconjugatepivekimabsunirineimgn632incombinationwithvenetoclaxvenandazacitidineazaforpatientswithcd123positiveaml AT jeyakumard aphase1b2studyofthecd123targetingantibodydrugconjugatepivekimabsunirineimgn632incombinationwithvenetoclaxvenandazacitidineazaforpatientswithcd123positiveaml AT walterrb aphase1b2studyofthecd123targetingantibodydrugconjugatepivekimabsunirineimgn632incombinationwithvenetoclaxvenandazacitidineazaforpatientswithcd123positiveaml AT deangelodj aphase1b2studyofthecd123targetingantibodydrugconjugatepivekimabsunirineimgn632incombinationwithvenetoclaxvenandazacitidineazaforpatientswithcd123positiveaml AT erbahp aphase1b2studyofthecd123targetingantibodydrugconjugatepivekimabsunirineimgn632incombinationwithvenetoclaxvenandazacitidineazaforpatientswithcd123positiveaml AT advania aphase1b2studyofthecd123targetingantibodydrugconjugatepivekimabsunirineimgn632incombinationwithvenetoclaxvenandazacitidineazaforpatientswithcd123positiveaml AT gastaudl aphase1b2studyofthecd123targetingantibodydrugconjugatepivekimabsunirineimgn632incombinationwithvenetoclaxvenandazacitidineazaforpatientswithcd123positiveaml AT thomasx aphase1b2studyofthecd123targetingantibodydrugconjugatepivekimabsunirineimgn632incombinationwithvenetoclaxvenandazacitidineazaforpatientswithcd123positiveaml AT todiscoe aphase1b2studyofthecd123targetingantibodydrugconjugatepivekimabsunirineimgn632incombinationwithvenetoclaxvenandazacitidineazaforpatientswithcd123positiveaml AT pemmarajun aphase1b2studyofthecd123targetingantibodydrugconjugatepivekimabsunirineimgn632incombinationwithvenetoclaxvenandazacitidineazaforpatientswithcd123positiveaml AT mendezl aphase1b2studyofthecd123targetingantibodydrugconjugatepivekimabsunirineimgn632incombinationwithvenetoclaxvenandazacitidineazaforpatientswithcd123positiveaml AT delafuentea aphase1b2studyofthecd123targetingantibodydrugconjugatepivekimabsunirineimgn632incombinationwithvenetoclaxvenandazacitidineazaforpatientswithcd123positiveaml AT gaidanog aphase1b2studyofthecd123targetingantibodydrugconjugatepivekimabsunirineimgn632incombinationwithvenetoclaxvenandazacitidineazaforpatientswithcd123positiveaml AT curtia aphase1b2studyofthecd123targetingantibodydrugconjugatepivekimabsunirineimgn632incombinationwithvenetoclaxvenandazacitidineazaforpatientswithcd123positiveaml AT boisseln aphase1b2studyofthecd123targetingantibodydrugconjugatepivekimabsunirineimgn632incombinationwithvenetoclaxvenandazacitidineazaforpatientswithcd123positiveaml AT recherc aphase1b2studyofthecd123targetingantibodydrugconjugatepivekimabsunirineimgn632incombinationwithvenetoclaxvenandazacitidineazaforpatientswithcd123positiveaml AT schliemannc aphase1b2studyofthecd123targetingantibodydrugconjugatepivekimabsunirineimgn632incombinationwithvenetoclaxvenandazacitidineazaforpatientswithcd123positiveaml AT vyasp aphase1b2studyofthecd123targetingantibodydrugconjugatepivekimabsunirineimgn632incombinationwithvenetoclaxvenandazacitidineazaforpatientswithcd123positiveaml AT slosscm aphase1b2studyofthecd123targetingantibodydrugconjugatepivekimabsunirineimgn632incombinationwithvenetoclaxvenandazacitidineazaforpatientswithcd123positiveaml AT wangj aphase1b2studyofthecd123targetingantibodydrugconjugatepivekimabsunirineimgn632incombinationwithvenetoclaxvenandazacitidineazaforpatientswithcd123positiveaml AT malcolmka aphase1b2studyofthecd123targetingantibodydrugconjugatepivekimabsunirineimgn632incombinationwithvenetoclaxvenandazacitidineazaforpatientswithcd123positiveaml AT zweidlermckaypa aphase1b2studyofthecd123targetingantibodydrugconjugatepivekimabsunirineimgn632incombinationwithvenetoclaxvenandazacitidineazaforpatientswithcd123positiveaml AT sweetkl aphase1b2studyofthecd123targetingantibodydrugconjugatepivekimabsunirineimgn632incombinationwithvenetoclaxvenandazacitidineazaforpatientswithcd123positiveaml AT daverng phase1b2studyofthecd123targetingantibodydrugconjugatepivekimabsunirineimgn632incombinationwithvenetoclaxvenandazacitidineazaforpatientswithcd123positiveaml AT montesinosp phase1b2studyofthecd123targetingantibodydrugconjugatepivekimabsunirineimgn632incombinationwithvenetoclaxvenandazacitidineazaforpatientswithcd123positiveaml AT aribia phase1b2studyofthecd123targetingantibodydrugconjugatepivekimabsunirineimgn632incombinationwithvenetoclaxvenandazacitidineazaforpatientswithcd123positiveaml AT martinellig phase1b2studyofthecd123targetingantibodydrugconjugatepivekimabsunirineimgn632incombinationwithvenetoclaxvenandazacitidineazaforpatientswithcd123positiveaml AT altmanj phase1b2studyofthecd123targetingantibodydrugconjugatepivekimabsunirineimgn632incombinationwithvenetoclaxvenandazacitidineazaforpatientswithcd123positiveaml AT robozg phase1b2studyofthecd123targetingantibodydrugconjugatepivekimabsunirineimgn632incombinationwithvenetoclaxvenandazacitidineazaforpatientswithcd123positiveaml AT wanges phase1b2studyofthecd123targetingantibodydrugconjugatepivekimabsunirineimgn632incombinationwithvenetoclaxvenandazacitidineazaforpatientswithcd123positiveaml AT burkepw phase1b2studyofthecd123targetingantibodydrugconjugatepivekimabsunirineimgn632incombinationwithvenetoclaxvenandazacitidineazaforpatientswithcd123positiveaml AT jeyakumard phase1b2studyofthecd123targetingantibodydrugconjugatepivekimabsunirineimgn632incombinationwithvenetoclaxvenandazacitidineazaforpatientswithcd123positiveaml AT walterrb phase1b2studyofthecd123targetingantibodydrugconjugatepivekimabsunirineimgn632incombinationwithvenetoclaxvenandazacitidineazaforpatientswithcd123positiveaml AT deangelodj phase1b2studyofthecd123targetingantibodydrugconjugatepivekimabsunirineimgn632incombinationwithvenetoclaxvenandazacitidineazaforpatientswithcd123positiveaml AT erbahp phase1b2studyofthecd123targetingantibodydrugconjugatepivekimabsunirineimgn632incombinationwithvenetoclaxvenandazacitidineazaforpatientswithcd123positiveaml AT advania phase1b2studyofthecd123targetingantibodydrugconjugatepivekimabsunirineimgn632incombinationwithvenetoclaxvenandazacitidineazaforpatientswithcd123positiveaml AT gastaudl phase1b2studyofthecd123targetingantibodydrugconjugatepivekimabsunirineimgn632incombinationwithvenetoclaxvenandazacitidineazaforpatientswithcd123positiveaml AT thomasx phase1b2studyofthecd123targetingantibodydrugconjugatepivekimabsunirineimgn632incombinationwithvenetoclaxvenandazacitidineazaforpatientswithcd123positiveaml AT todiscoe phase1b2studyofthecd123targetingantibodydrugconjugatepivekimabsunirineimgn632incombinationwithvenetoclaxvenandazacitidineazaforpatientswithcd123positiveaml AT pemmarajun phase1b2studyofthecd123targetingantibodydrugconjugatepivekimabsunirineimgn632incombinationwithvenetoclaxvenandazacitidineazaforpatientswithcd123positiveaml AT mendezl phase1b2studyofthecd123targetingantibodydrugconjugatepivekimabsunirineimgn632incombinationwithvenetoclaxvenandazacitidineazaforpatientswithcd123positiveaml AT delafuentea phase1b2studyofthecd123targetingantibodydrugconjugatepivekimabsunirineimgn632incombinationwithvenetoclaxvenandazacitidineazaforpatientswithcd123positiveaml AT gaidanog phase1b2studyofthecd123targetingantibodydrugconjugatepivekimabsunirineimgn632incombinationwithvenetoclaxvenandazacitidineazaforpatientswithcd123positiveaml AT curtia phase1b2studyofthecd123targetingantibodydrugconjugatepivekimabsunirineimgn632incombinationwithvenetoclaxvenandazacitidineazaforpatientswithcd123positiveaml AT boisseln phase1b2studyofthecd123targetingantibodydrugconjugatepivekimabsunirineimgn632incombinationwithvenetoclaxvenandazacitidineazaforpatientswithcd123positiveaml AT recherc phase1b2studyofthecd123targetingantibodydrugconjugatepivekimabsunirineimgn632incombinationwithvenetoclaxvenandazacitidineazaforpatientswithcd123positiveaml AT schliemannc phase1b2studyofthecd123targetingantibodydrugconjugatepivekimabsunirineimgn632incombinationwithvenetoclaxvenandazacitidineazaforpatientswithcd123positiveaml AT vyasp phase1b2studyofthecd123targetingantibodydrugconjugatepivekimabsunirineimgn632incombinationwithvenetoclaxvenandazacitidineazaforpatientswithcd123positiveaml AT slosscm phase1b2studyofthecd123targetingantibodydrugconjugatepivekimabsunirineimgn632incombinationwithvenetoclaxvenandazacitidineazaforpatientswithcd123positiveaml AT wangj phase1b2studyofthecd123targetingantibodydrugconjugatepivekimabsunirineimgn632incombinationwithvenetoclaxvenandazacitidineazaforpatientswithcd123positiveaml AT malcolmka phase1b2studyofthecd123targetingantibodydrugconjugatepivekimabsunirineimgn632incombinationwithvenetoclaxvenandazacitidineazaforpatientswithcd123positiveaml AT zweidlermckaypa phase1b2studyofthecd123targetingantibodydrugconjugatepivekimabsunirineimgn632incombinationwithvenetoclaxvenandazacitidineazaforpatientswithcd123positiveaml AT sweetkl phase1b2studyofthecd123targetingantibodydrugconjugatepivekimabsunirineimgn632incombinationwithvenetoclaxvenandazacitidineazaforpatientswithcd123positiveaml |